Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators

US9573950B2 · kind B2 · utility

Assignee

• Abb Vie Deutschland Gmbh & Co. KG · DE

Inventors

• Gisela Backfisch · Dossenheim, DE
• Margaretha Henrica Maria Bakker · Ludwigshafen, DE
• Günter BLAICH · Ludwigshafen, DE
• Wilfried Braje · Ludwigshafen, DE
• Karla Drescher · Ludwigshafen, DE
• Thomas ERHARD · Ludwigshafen, DE
• Andreas Haupt · Ludwigshafen, DE
• Hannes Fiepko KOOLMAN · North Chicago, US
• Viktor Lakics · Budapest, HU
• Anna LINSENMEIER · Ludwigshafen, DE
• Helmut Mack · Ludwigshafen, DE
• Raimund PETER · Wilmslow, GB
• Ana-Lucia Relo · Ludwigshafen, DE
• Xiaona Zhao · Tianjin, CN
• Jincheng Wang · Tianjin, CN

Key dates

• Filing date: Mar 13, 2015
• Grant date: Feb 21, 2017
• Expiry date: Mar 13, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compound of formula (I) as tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, useful for modulating the 5-HT2C receptor and preventing and/or treating conditions and disorders that respond to the modulation of the 5-HT2C receptor. The present invention also relates to methods for producing compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for preventing or treating conditions and disorders that respond to the modulation of the 5-HT2C receptor by administering compounds of formula (1) or pharmaceutical compositions thereof.